Edwards Lifesciences Corporation (EW), valued at $45.2 billion, is set to announce its fiscal Q3 earnings on Oct. 30. Analysts predict a profit of $0.59 per share, down 11.9% from the previous year. For fiscal 2025, a profit of $2.50 per share is expected, with an EPS growth of 11.2% in fiscal 2026.

EW shares have risen 17.9% in the past year, outperforming the S&P 500 and XLV. Q2 results exceeded expectations, with revenue up 11.9% year-over-year. The company raised its fiscal 2025 guidance, expecting sales growth between 9-10% and adjusted EPS at the high end of $2.40 to $2.50.

Analysts give EW a “Moderate Buy” rating, with a mean price target of $86.83, suggesting a 12.7% potential upside.

Read more at Yahoo Finance: Here’s What to Expect From Edwards Lifesciences’ Next Earnings Report